Are we on the brink of a revolution in treating HER2-positive early breast cancer? Paolo Tarantino, the esteemed 2025 Yvonne’s “Top Voice” Award Winner, Clinical Research Fellow at Dana-Farber Cancer Institute, and Visiting Professor at McGill University, thinks so. In a recent LinkedIn post (https://www.linkedin.com/feed/update/urn:li:activity:7420598613522685952/), Tarantino hints at a seismic shift in treatment paradigms. For nearly a decade, neoadjuvant TCHP has been the go-to therapy for stage II-III HER2-positive breast cancer. But here's where it gets controversial: Tarantino suggests we’re moving toward multiple new standards—more personalized, more precise. In his thought-provoking editorial for the Journal of Clinical Oncology (https://ascopubs.org/doi/10.1200/JCO-25-02855), titled Rise and Fall of Neoadjuvant Carboplatin for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer, he dissects the NeoCARHP phase 3 trial and its implications. This isn’t just about swapping one drug for another; it’s about reimagining how we approach treatment algorithms. And this is the part most people miss: the shift could mean better outcomes for patients, but it also raises questions about accessibility and cost. Is personalized medicine the future, or are we overcomplicating a tried-and-true approach? Tarantino’s insights are a must-read for anyone in oncology. Dive into the full article and explore more of his work on OncoDaily (https://oncodaily.com/tag/paolo-tarantino). But first, ask yourself: Are we ready for this change? Let’s discuss in the comments—agree or disagree, your perspective matters!
